The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Pain Visual Analogue Score (VAS)
研究概览
简要总结
This is a Phase II, single-center, fixed dose, open label trial to explore the safety, tolerability and efficacy of a 25mg dose of psilocybin in cancer patients with MDD. The study population will include adult men and women, 18 years of age or above, with MDD, diagnosed with a malignant neoplasm. MDD is defined as those who meet DSM 5 diagnostic criteria for a single or recurrent episode of MDD without psychotic features. A diagnosis of a malignant neoplasm is defined as having a diagnostic code from C00 to C97 according to the ICD-10.
详细描述
Recent randomized, placebo-controlled clinical trials of psilocybin therapy for anxiety and depression associated with cancer diagnosis showed significant improvement in study endpoints reflecting psychological distress, as compared to placebo. The effects of a single psilocybin therapy session endured for up to six months with no specific follow-up care. In this study, we aim to explore the safety and efficacy of psilocybin therapy in cancer patients, diagnosed with Major Depressive Disorder (MDD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or above at Screening (V1)
- •Currently meet criteria for MDD (single or recurrent episode as defined by DSM 5; if single episode, duration of more or equal to 3 months) based on medical records, clinical assessment and documented completion of the MINI version 7.0.2
- •A diagnosis of a malignant neoplasm with a diagnostic code from C00 to C97 according to the International Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)
- •HAM D 17 score ≥18 at Screening (V1) and at Baseline (V2)
- •Are not currently taking any antidepressant and/or antipsychotic medications, or medical cannabis, at Screening (V1)
- •Able to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits
- •Has capacity to consent (assessed via investigator judgement)
排除标准
- •Psychiatric Exclusion Criteria:
- •Current or past history of schizophrenia, psychotic disorder, bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, or borderline personality disorder, as assessed by medical history and a structured clinical interview (MINI version 7.0.2)
- •Current (within the past year) alcohol or drug use disorder as defined by DSM 5 (MINI 7.0.2) at Screening (V1)
- •Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, at Screening or at Baseline, or; (2) suicidal behaviors within the past year, or; (3) clinical assessment of significant suicidal risk during subject interview
- •Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin
- •General Medical Exclusion Criteria:
- •Women who are pregnant, nursing, or planning a pregnancy. Women and men of child bearing potential and who are sexually active must agree to use an acceptable contraceptive method throughout their participation in the study. Women of child bearing potential must have a negative urine pregnancy test at Screening (V1) and Baseline (V2)
- •Cardiovascular conditions: recent stroke (<1 year from signing of ICF), recent myocardial infarction (<1 year from signing of ICF), uncontrolled hypertension (blood pressure >140/90) or clinically significant arrhythmia within 1 year of signing the ICF
- •Uncontrolled or insulin dependent diabetes
- •Seizure disorder
- •Positive urine drug screen for illicit drugs or drugs of abuse at V1 and V
- •Any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion in conjunction with the medical monitor
- •Current enrollment in any investigational drug or device study or participation in such within 30 days of Screening.
- •Abnormal and clinically significant results on the physical examination, vital signs, ECG, or laboratory tests at Screening (V1) that in the investigator's opinion may consistute a risk for an individual who is explosed to psilocybin. This includes platelets below 50,000 platelets per cubic millimeter of blood, liver function tests three times the upper limit of normal, creatine two times above the normal range. Clinically significant abnormal electrolytes or low hemoglobin (below 8 g/L) should be corrected and rechecked
- •Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study
- •Use of psychedelics, including psilocybin but excluding medical marijuana, within the past 12 months and use of psychedelics during the current episode of depression
- •Concurrent or recent chemotherapy or radiation therapy, that impairs general level of phsyical functioning.
研究组 & 干预措施
Psilocybin 25mg
Psilocybin 25mg Single does with supportive conditions.
干预措施: Psilocybin (Drug)
结局指标
主要结局
Pain Visual Analogue Score (VAS)
时间窗: 8 weeks
Change in use of pain medications from Baseline (Day -1 \[V2\]) to Week 8 (V7) Minimum score: 0 Maximum Score: 10 Higher score is not indicative of a better outcome.
The Montgomery-Åsberg Depression Rating Scale (MADRS)
时间窗: 8 weeks
Ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Minimum Score: 0 Maximum Score: 60 Higher Score is indicative of greater depression
Patient EQ-5D-5L
时间窗: 8 weeks
EQ-5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Participant EQ 5D 5L score change from Baseline (Day -1 \[V2\]) to subsequent follow up visits. Minimum: 0 Maximum: 20 Higher Score is indicative of worsening outcome.
5 Dimension Altered State of Consciousness (5D-ASC)
时间窗: 8 weeks
Summary of the 5D-ASC on the day of psilocybin dosing. o Links between psychedelic intensity and experience (via the 5D-ASC) and depression and anxiety outcomes will also be explored and patient experience and acceptability of the treatment summarised at V3 and V4. This has 11 subscales, and higher scores are indicative of good outcomes.
Scale To Assess Therapeutic Relationship: Patient (STAR-P)
时间窗: 8 weeks
Therapeutic alliance of the clinician and patient, as rated using the STAR-C and STAR-P respectively will be assessed at Baseline, along with assessing correlations with this measure and primary and secondary outcomes as a possible predictor of response Minimum: 0 Maximum: 48 Higher Score is indicative of good outcome.
Maudley Visual Analogue Scale (VAS) Change.
时间窗: 8 weeks
Change in Maudsley VAS change scores from Baseline Minimum score: -50 Maximum Score: 50 Higher score is indicative of a better outcome.
State-Trait Anxiety Inventory (STAI)
时间窗: 8 weeks
Psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis Minimum: 20 Maximum: 80 Higher Score is indicative of worsening outcome.
Changes in electrocardiographs.
时间窗: 8 weeks
Abnormal and clinically significant results on the ECG, that in the investigator's opinion may constitute a risk for an individual who is exposed to psilocybin.
Sheehan Disability Score (SDS)
时间窗: 8 weeks
SDS score change from Baseline Minimum: 0 Maximum: 30 Higher Score is indicative of worsening outcome.
Quick Inventory of Depressive Symptomatology Self reported (QIDS-SR)
时间窗: 8 weeks
16-Item quick inventory of depressive symptomatology. Minimum score: 0 Maximum Score: 16 Higher Score is indicative of worsening depression.
Maudsley Visual Analogue Scale (VAS) current
时间窗: 8 weeks
Minimum score: -50 Maximum Score: 50 Higher score is indicative of a better outcome.
Hamilton Anxiety Rating Scale-A (HAM-A)
时间窗: 8 weeks
The Hamilton Anxiety Rating Scale (HAM-A) is a widely used and well-validated tool for measuring the severity of a patient's anxiety. It should be administered by an experi- enced clinician. The HAM-A probes 14 parameters and takes 15-20 minutes to complete the interview and score the results. Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. Minimum Score: 0 Maximum Score: 56 Higher Score is indicative of worsening Depression
National Institute of Health Healing Experience of All Life Stressors (NIH-HEALS)
时间窗: 8 weeks
Psycho-social-spiritual healing in NIH-HEALS total score change from Baseline (Day -1 \[V2\]) to Weeks 1 (V5), 3 (V6), and 8 (V7). Additionally changes in the three factor scores on this measure will be assessed for change at the same timepoints: Connection; Reflection and Introspection; Trust and Acceptance.Healing Experience of All Life Stressors (NIH-HEALS) was developed by the NIH Clinical Center Pain and Palliative Care Service as a psycho-social-spiritual measure of healing that assesses positive transformation in response to challenging life events. It is a self-report, 35-item questionnaire.
DS-II
时间窗: 8 weeks
Change in DS-II factor scores from Baseline. Minimum: 0 Maximum: 32 Higher Score is indicative of worsening outcome.
Caregiver Oncology Quality of Life Questionnaire (CarGOQol)
时间窗: 8 weeks
CarGOQol score change from Baseline (Day -1 \[V2\]) to subsequent follow up visits (this assessment is not mandatory) Minimum: 0 Maximum: 116 Higher Score is indicative of worsening outcome.
Scale To Assess Therapeutic Relationship: Clinician. (STAR-C)
时间窗: 8 weeks
Therapeutic alliance of the clinician and patient, as rated using the STAR-C and STAR-P respectively will be assessed at Baseline, along with assessing correlations with this measure and primary and secondary outcomes as a possible predictor of response Minimum: 0 Maximum: 48 Higher Score is indicative of good outcome.
次要结局
未报告次要终点